EP240: Beyond Mold: The Continent of the Cell Danger Response - Part 2 - Andrew Heyman, MD, MHSA
In a Nutshell
Dr. Heyman argues that the Shoemaker model's focus on actinobacteria and MARCoNS is based on weak evidence, and that endotoxins, gut dysbiosis, and hidden infections are more significant drivers of the cell danger response. Treatment requires a sequenced approach: first remove triggers and reduce inflammation (CDR1), then rebuild mitochondrial function and metabolism (CDR2), and finally restore safety signals and resilience (CDR3). Key interventions include phospholipid therapy, gut healing with butyrate and immunoglobulins, autonomic retraining via HRV and limbic work, and careful timing of hormones, peptides, and mitochondrial support only after inflammation is controlled.
These notes were generated by AI and may contain inaccuracies.
Dr. Heyman was involved from the beginning of the original research papers on actinobacteria. There are approximately 6,000 varieties worldwide that are hardy organisms capable of living in both desert-dry and watery environments. They are communal organisms that congregate together in living spaces and are motile, developing pseudopods to pull themselves across surfaces. When enough accumulate in one area, they release chemical compounds that attract additional actinobacteria from a distance.
The 42% actinobacteria statistic came from GENIE testing based on MAP kinases, but Dr. Heyman questions the specificity of MAP kinases for actinobacteria. He describes this as a series of conjectures: if MAP kinases are turned on, it must be actinobacteria, and if 42% of GENIEs show that pattern, then 42% of people must be suffering from actinobacteria exposure.
Dr. Heyman acknowledges that measuring actinobacteria in the environment and on skin leads to recommendations for special air filters and small particle cleaning. However, he questions whether these strategies actually address the assigned problem. He notes that good air filtration and small particle cleaning benefit anyone by reducing dust levels, cleaning microbial surfaces, and decreasing pathogenic load, regardless of whether actinobacteria are the primary issue.
The same analysis applies to MARCoNS, where treating nasal dysbiosis might be beneficial even if the specific organisms aren't the actual problem. Dr. Heyman believes the approach restores normal microbial milieu rather than specifically targeting the assigned organisms.
Dr. Heyman observes that some patients develop extreme personal hygiene regimens involving aggressive topical preparations and loofahs. He notes that patients may go to extremes such as living in bubbles, tents, or forests, or never leaving their homes because everything outside feels threatening.
He states that the behavior and sense of fear about skin organisms or the outside world is worse than the actual illness itself, as it cements the person in CDR through daily re-traumatization. Dr. Heyman advocates for basic hygiene practices like regular bathing and cleaning without going to extremes.
Dr. Heyman considers the data stronger for endotoxins and lipopolysaccharides triggering inflammatory responses compared to actinobacteria. He also includes beta glucans in this category as compounds that turn on toll-like receptors, PAMPs and DAMPs, and the dectin pathway, which trigger significant inflammatory responses.
Environmental sources of endotoxins include living with animals, farms, leaking sewer pipes, septic tank issues, and unsealed sump pumps. The gut itself can be a major generator of endotoxins from gram-negative bacteria. Dr. Heyman references literature showing that prolonged physical exertion creates gut dysbiosis with enormous endotoxin outpouring, which interferes with muscle contraction and causes athletes to collapse during events like Ironman competitions.
Dr. Heyman identifies good probiotics as one of the most tried and true methods for cleaning up gram-negative bacteria. He recommends testing the gut microbiome, measuring food exposures, leakiness, zonulin, and endotoxin production. Natural compounds he uses include berberine, cat's claw, grapefruit seed extract, and black walnut to address pathogens including gram negatives.
He notes that both cholestyramine and Welchol have roles in binding endotoxins as part of their natural function.
Dr. Heyman's clinic was previously a key chelation clinic run by an integrative rheumatologist for decades, running 30-40 IVs daily including EDTA, DMPS, alpha-lipoic acid, and hydrogen peroxide. They were a study site for the big EDTA cardiovascular disease study.
A critical incident involved a patient who had a psychotic episode during EDTA administration, ripping out his IV, picking up a rock, and banging it against car windows while banging his head against cars. The patient had undiagnosed Lyme disease and likely mold exposure, creating a significant inflammatory state when EDTA was administered, pushing heavy metals around his system in ways his body couldn't compensate.
Dr. Heyman learned that inflammatory load must be reduced first using binders, cleaning up the home, and gentle detox with phospholipids and bile support using bitters such as artichoke and dandelion. Heavy metal challenges should only be done after passing the visual test. He uses Enviromedica, which includes charcoal, clay, and chlorella, and may add oral DMSA later in the process.
For chemicals, he uses phospholipids, chlorella, cracked cell wall chlorella, phase 2 support with glycine and taurine, glutathione support, saunas, and aged garlic extract, which has shown to help reduce cadmium in kidneys.
Dr. Heyman worked directly with and taught with Patricia Kane, who advocated lipid replacement therapy. He found that patients often reported feeling better with phospholipid replacement, which was uncommon with other mold approaches.
The body is not designed to react to lipids, making them safe for hyperreactive patients. Mitochondria have a double lipid bilayer where the outer membrane is mostly phosphatidylcholine and inner components include phosphatidylinositol, phosphatidylethanolamine, and cardiolipins. Cell membrane turnover throughout the body can take a year or longer.
Dr. Heyman starts phospholipid therapy immediately because: it is safe for reactive patients, it functions as a detoxifying agent, it provides direct mitochondrial support, and the process is slow requiring early initiation. He considers phospholipids critical for patient recovery and states that if patients can afford only one supplement, it should be phospholipids.
Dr. Heyman's research group was approached by the school of pharmacy at Beijing approximately 15 years ago regarding RG3 as an exciting candidate compound for neuroprotection.
Chinese ginseng contains a family of biologically active compounds called ginsenosides with different families or lines including the RB line and RG line. The RG line ginsenosides, particularly RG1 and RG3, demonstrated exciting ability to reduce neuroinflammation and blunt microglial activation. Microglial cells are specialized macrophages in the brain, and macrophages function as the immune system's innate defenders. When triggered through the DCTIN pathway, macrophages shift into an M1 phenotype and overproduce inflammatory compounds and cytokines. RG3 and RG1 showed strong ability to blunt cytokine production in microglial cells.
RG3 also activates the sirtuin pathway, which participates in the repair cycle and anti-aging mechanisms. The school of pharmacy approached the clinical team because they were excited about RG3 but needed guidance on clinical administration. This led to development of different formulations for therapeutic RG3 delivery, beginning with a nasal spray. The team combined RG3 with nicotinamide riboside as a direct NAD precursor, creating complementary effects for reducing brain inflammation and encouraging repair from injury.
The nasal spray formulation, called Synapsin, combines RG3 with the NAD precursor. Patients with traumatic brain injury history, severe cognitive deficits, or decline receive consideration for this therapy. For direct cognitive issues such as early dementia, Parkinson's, or TBI, the nasal spray gets recommended. A chewable formulation was later developed using a special matrix that allows direct crossing of the buccal mucosa for very high intracellular levels. The chewable delivers RG3, testosterone, BPC 157, curcumin, and even VIP systemically. For generalized fatigue and post-exertional malaise targeting mitochondria broadly, the chewable Synapsin is used. For patients with flatlined cortisol curves, the nasal spray version is preferred.
Phase two of CDR1 treatment focuses on the pathogen reduction phase, clearing hidden infections including vector-borne infections, herpes viruses, SIBO, fungal burdens, biofilms, and restoring microbiome homeostasis. Lyme and mold are considered kissing cousins. The approach addresses Lyme first rather than mold because internal whole-body dysbiosis occurs as part of this illness. Treating the nose addressed one body compartment, but the gut represents another major compartment, with potential extension to skin and others.
Candida overgrowth, parasites, and reactivated viruses all form part of this picture. SIBO presents frequently in this patient population due to lack of peristalsis allowing bacteria to move into the small intestines, requiring antimicrobial support. Candida releases beta-glucans into the system similar to external fungal mold exposure. Standard treatment includes cat's claw, berberine, grapefruit seed extract, black walnut, and artemisinin to reduce microbial burden. Viral testing occurs only for severely sick patients with temperature instability, with most viral testing deferred until reassessment at the end of CDR2. Most viruses disappear when other precursor issues get addressed properly.
Long COVID patients appear to be in a pro-inflammatory state consistent with CDR. Literature shows COVID can persist in the gut, but no tried-and-true protocol exists for addressing spike protein and residual COVID. The general approach of removing mold, fixing the gut, balancing hormones, removing exposure, and detoxifying leads to improvement in long COVID symptoms.
MARCoNS releases compounds that interfere with VIP therapy effects, with the theory that palytoxins or polycyclic ethers impair mitosomes and suppress ribosome function, reducing VIP effectiveness. Literature on MARCoNS is mixed, with some studies indicating its presence is protective against other pathogens. The presence of polycyclic ethers and palytoxins produced by MARCoNS became a pillar of treatment in the CIRS world. However, no direct relationship appears between MARCoNS presence and mitosome suppression in clinical observation.
Sinus dysbiosis more broadly creates a pro-inflammatory state releasing toxic compounds that reach the brain, similar to gut dysbiosis. Companies like Sinus Key provide better assessment of the nasal microbial landscape. Treatment of the nose appears important, but the specific target of treatment remains uncertain. Fungal elements can appear in the nose, and the ENT approach from Donald Dennis in Georgia has produced significant patient improvement.
Fungal colonization represents the most controversial aspect of this model, involving low-grade colonization of body compartments and tissues, particularly lungs and gut. Itraconazole has proven most effective for ridding the body of fungal infections, but literature support for itraconazole in low-grade fungal colonization is minimal. Natural antifungals are preferred over itraconazole due to liver impact concerns, especially given compromised detox pathways in these patients. Liver Matrix, a liver glandular product, provides liver support from day one.
Literature actually shows itraconazole has positive benefits for the VDAC receptor rather than antagonistic effects, and demonstrates protective effects for the brain. However, oral itraconazole prescriptions are rarely used due to strength and potential negative impact on detox pathways. Nasal spray application is considered more liberally when nasal findings warrant treatment.
Parasite testing limitations exist, with even the best tests potentially catching only 8% of actual presence. Pair Wellness, run by Dr. Raphael D'Angelo, provides the best parasite testing available. Most results show antamoeba and blastocystis, which may not be clinically relevant parasites. A standard two-month regimen of natural antimicrobials and antiparasitics includes black walnut, artemisinin, oregano oil, cat's claw, and berberine. This provides a nod to the likelihood that most people deserve some level of parasite cleanse, especially those consuming sushi. Die-off reactions occur but are managed with binder support, phospholipids, drainage mechanisms, and glutathione already in place. Retesting may occur if CDR1 persists, but deeper investigation is rarely needed.
Phase three of CDR1 treatment focuses on healing the gut, rebuilding nutrition, addressing gut mucosa, probiotics, and potentially bovine immunoglobulins. Bovine immunoglobulins help mitigate lipopolysaccharides. Food panels and microbiome/gut health panels assess diversity and amount of microbiome, along with markers like lipopolysaccharides, zonulin, and inflammatory compounds like EPX. Stool testing captures only the lower third of the colon and remains somewhat unreliable. Companies like Biomes and GI-MAP provide microbiome assessment, with Jonah using AI for more sophisticated measurement.
Soluble fiber fixes many gut issues and represents a foundational approach often overlooked. Prebiotics contribute to gut health. Probiotic selection remains challenging with shifting trends, such as the recent Akkermansia focus. Akkermansia is expensive as a probiotic, and excessive levels can be detrimental to the brain and neurodegenerative diseases. Diversity matters more than individual markers, and probiotic markers themselves are unreliable.
Immunoglobulin therapy has validity in the literature, though source choice matters. Orthomolecular's SBI Protect demonstrates mitigation of dairy sensitivities. An avian egg albumin immunoglobulin avoids triggering reactions common with bovine sources or original colostrum. Glutamine shows moderate literature support for sealing the gut lining despite being touted as the compound for leaky gut. Butyrate and calcium magnesium butyrate receive strong support following the Patricia Kane approach.
Butyrate serves as an extraordinarily potent agent for recharging the digestive tract. Probiotics occupy a unique position between prebiotics and true probiotics, nourishing and helping to grow resident bacteria that are unique to each individual. Imaging studies demonstrate that probiotics allow a person's microbiome fingerprint to flourish. However, a fair amount must be taken for probiotics to work effectively. Patients with Crohn's disease and ulcerative colitis have shown good results with high-dose Dr. Ohira's probiotics combined with immunoglobulins.
The gut represents a blind spot in traditional CIRS models. Reducing endotoxin burden, sealing up the gut lining, and changing diet are essential steps. There is no one-size-fits-all diet, as different people have different food needs on top of restoring normal microbiome support.
The microbiome must be addressed before mitochondrial function can be properly restored. Impaired mitochondrial function will persist if the microbiome is not corrected first. The gut must be treated before mitochondria are targeted.
EMDR and limbic retraining serve as safety signals that can be overlaid across every stage of the CDR process. These interventions shine particularly with hyperreactive mast cell patients who are in such an alarm state that any method to reduce reactivity becomes valuable. Traditional treatments include ketotifen and cromolyn, along with microdosing GLP-1s.
The parasympathetic route provides another avenue through toning up the autonomic nervous system via EMDR, limbic training, or vagal nerve stimulators. Patients are instructed to track their HRV from day one. When patients are in dire straits, overwhelmed, and unable to take medications, limbic retraining is often added from the beginning. EMDR is considered tried and true. The home device Bi-Tap replicates EMDR and allows patients without practitioner access to attempt resetting the limbic response.
Hypermobility and Ehlers-Danlos syndrome are viewed as purely genetic rather than acquired conditions. These patients tend to be sicker, harder to treat, and exhibit higher levels of inflammation. A clinic in New Orleans focuses on connective tissue issues and associated inflammatory states. High-dose vitamin C and collagen-based therapies have not demonstrated significant effects in this population.
The connective tissue coiling is generally looser, allowing cells that traffic in peripheral connective tissue and release MMP-9 and TGF-beta 1, such as TH17 cells, to escape. This results in higher levels of systemic inflammation because cells are not trapped in the coiling. No specific therapeutic strategy exists for connective tissue repair. Higher dosing needs to be employed in this population. The POTS-EDS-mast cell triad represents a commonly discussed pattern, but no specific treatment changes have been identified based on this triad. Connective tissue does not appear to tighten after proper therapy.
CDR1 contains three phases with specific gates that must be cleared to progress:
- Phase 1 involves silencing the alarm or trigger removal, requiring confirmation that the environment is safe, biotoxin markers improving, symptoms no longer tied to location, and passing the VCS test
- Phase 2 focuses on clearing hidden infections or pathogen reduction, requiring ideally a negative MARCoNS test, control of known infections, and managing any reactions
- Phase 3 addresses healing the gut and rebuilding nutrition, requiring improved permeability markers, addressed food stress, and rebuilt microbiome
Progression depends on seeing gates improving, as extracellular ATP cannot be directly measured as the first alarm. Testing categories include checking if the gut is okay, if food panels show issues, or if microbiome testing reveals candida or other problems. When patients gate through visual tests, show clearance of mycotoxins, demonstrate improved gut function, feel better, and are out of exposure, progression to CDR2 becomes appropriate.
CDR2, called the rebuild phase, occurs after the fire is out and the construction crew arrives to clear debris and repair damage. The construction crew includes TGF-beta 1, VEGF, proliferative physiology, a shift to M2 macrophages in the repair-focused inflammatory resolution state, hypometabolism, aerobic glycolysis, post-exertional malaise, increased anxiety, histamine issues, and adrenal fatigue.
Phase 4 within CDR2 focuses on metabolic efficiency and autonomic restoration or rebuilding the engines. Elevations of GDF-15 and FGF-21 may still be seen, with normalization expected as patients move out of CDR2.
Viral mitigation is addressed after completing CDR2 as part of the ready-to-heal gate for CDR3. This follows the CIRS model approach where getting out of mold, treating other infections, and healing the gut are prioritized before addressing long COVID or persistent viruses. By the end of CDR2, when mitochondrial restoration and broader metabolic restoration are complete, viruses are checked for reactivation and T-helper cell stance is evaluated. The hope is that viruses are already quiet because the immune system has come back online and can resuppress DNA viruses.
Aerobic glycolysis, also known as the Warburg effect or hypometabolism, occurs early in the process once a pro-inflammatory state is established and tissue destruction occurs. A transition to M2 macrophages happens, representing the cleanup crew rather than microglial activation. Some cells switch into aerobic glycolysis while others continue fighting in CDR1, creating a mosaicism pattern.
By definition, CDR2 is characterized by aerobic glycolysis. The trade-off is feeling worse while the body marshals resources for repair. Fueling the repair process requires providing substrates, nutrients, hormones, and peptides needed for mitochondria to rebuild.
Mitochondrial support tools include CoQ10, NAD or precursors, carnitine, B2, alpha-lipoic acid, and ribose. Introducing these tools too early in CDR1 could backfire by turning up the danger signal through extracellular ATP creation. SS-31, urolithin A, and methylene blue play specific roles in mitochondrial support.
Mitochondria shift from protective danger signal mode or battleship mode to less of a threat response and more of a health-supporting response in CDR2, becoming even more pronounced by CDR3.
Mitochondrial testing includes the MitoEnergetics IC (MiC Screen) and Mito-ION tests. The MiC Screen uses a sampling technology that stabilizes blood tissue for seahorse assay analysis. The Mito-ION examines citrate synthase activity and the electron transport chain, providing complementary information about mitochondrial numbers and function.
Seven repeatable patterns have been identified on MiC Screen testing. Pattern recognition dictates treatment approaches. Approximately 30 mitochondrial treatments on the market are worth exploring. Some treatments can interfere with mitochondrial functioning depending on the state. A personalized approach requires mapping where mitochondria are functioning to determine appropriate interventions.
An automated platform processes MiC Screen and Mito-ION data to produce personalized assessments and plans. This represents the central feature of the illness that requires proper language and understanding.
Hyperreactivity to food and light may occur in CDR2, potentially related to mitochondrial strain. Low-histamine diets, ketotifen, cromolyn, mast cell stabilizers, and antihistamines may be used while working to remove underlying triggers. The philosophy centers on load over reserve, where overloading the system and losing reserve leads to hyperreactive mode. As patients progress through CDR1 and CDR2, mast cell reactivity typically improves. The goal is improving resiliency rather than simply blunting responses.
Hormone and endocrine restoration includes cortisol regulation, thyroid function, sex hormones, and vitamin D optimization. Common patterns may include low antidiuretic hormone and low testosterone. The body may be guarding reserves when the tank is low. Tools for increasing hydration status and optimizing water balance in the CIRS realm show variable results.
Electrolytes can serve as a useful tool for hydration status alongside other hydration approaches. Desmopressin has shown variable results, sometimes causing issues rather than helping. Endocrine support such as sex hormones, adrenals, and thyroid should generally wait until CDR2 rather than being introduced during CDR1.
For a decade, the director of academic affairs role at the American Academy of Anti-Aging Medicine provided oversight of the largest global training organization on longevity therapy, hormone replacement, and peptides. Responsibilities included securing CME accreditation for events and vetting all lectures, speakers, and slides for scientific rigor, evidence basis, and freedom from commercial influence. This role offered a front-row view of advanced thinking on hormone replacement and longevity treatments.
The experience brought global exposure across continents, providing perspective on developments outside the mold and Lyme space. Some practitioners focus exclusively on hormones, peptides, and Botox while avoiding complex chronic illness cases. The mold and Lyme community sometimes exhibits insularity, missing valuable approaches from other medical lineages including peptide therapies beyond VIP.
Metabolic derangements appear when the system undergoes general stress and enters metaflammation, showing physiological distress. Stress literature indicates the body deprioritizes reproduction and digestion during threat states, resulting in a flattened cortisol curve. The system remains hypervigilant without clear sleep-wake signals, staying active because the body anticipates fighting a tiger rather than resting, digesting, or reproducing.
Fasting insulin, glucose, A1C, full thyroid panels, cortisol curves, reproductive hormones, nutrient status, and vitamin D represent core elements of a standard anti-aging metabolic workup. When paired with mitochondrial approaches, this combination yields optimal rebuilding outcomes. Androgens, testosterone, growth hormone, and thyroid support tissue rebuilding, while catabolic hormones like cortisol and insulin promote tissue breakdown.
In the classic CIRS model, ADH measurement requires both below-normal ADH plus elevated osmolality, with 294 serving as the cutoff for elevated osmolality. Low ADH alone does not indicate water balance issues. Discordance between low ADH and high osmolality signals imbalance. Two interventions include electrolyte supplementation and short courses of desmopressin every other night. This approach works only after clearing inflammation in CDR1; introducing desmopressin too early yields poor results because the signal cannot reach the brain effectively.
The MIC screen directly measures reactive oxygen species originating from mitochondria, indicating excessive exhaust and cellular overwork. High ROS findings direct the use of antioxidants and lipids, with urolithin A showing particular benefit as part of mitochondrial interventions.
Phase 4 includes autonomic rehabilitation focusing on parasympathetic tonification and sympathetic calming. Key measurement tools include heart rate variability, which has existed for decades but remains underutilized. Heart Math has conducted seminal research in this area. HRV measures timing between heartbeats in milliseconds, with greater relaxation and parasympathetic dominance correlating to increased variability.
Heart rate variability functions as a proxy measure for systemic inflammation. Loss of HRV indicates sympathetic dominance and elevated tissue CRP levels, linking this metric to numerous chronic illnesses. The double burden includes both mental stress and tissue-level stress creating background inflammation. Parasympathetic tone elevation shifts inflammatory states, which is why moving out of CDR1 and rebuilding in CDR2 requires elevated parasympathetic activity.
Low HRV falls between the teens and twenties, while better HRV ranges fall in the upper thirties and forties. Patients with mold and Lyme conditions experience significant stress that typically drives low HRV, with approximately 20% maintaining preserved HRV despite illness. Not all patients require deep trauma work such as EMDR, though some benefit from stress resiliency training.
A partnership with Same Here (samehere.org) provides access to integrative psychiatrists specializing in stress and emotional issues operating on a continuum rather than binary categories. The organization conducts stress resiliency training in schools, hospitals, and workplaces while offering telemedicine access to experts and an app for self-reported stress assessment. Their approach encompasses mind-body work, EMDR, DNRS, and low-dose naltrexone.
Progression to CDR3 requires normalization of GDF-15, FGF-21, MMP9, near-normal TGF beta 1, VEGF restoration, continued VCS passage, hormonal restoration, and HRV indicating nervous system capacity. The environment must be addressed, microbes mitigated, inflammation normalized, danger mitokine signals decreased, hormones restored, and fluid balance achieved before entering phase 5.
TGF beta 1 serves as a signal indicating whether the body remains in active healing mode. The assay changed from a one-step to a two-step methodology, expanding the range and making direct application of old ranges inappropriate. Current ranges span 2,000 to 22,000 compared to the previous 0 to 2,800 normal range. A rule of thumb targets TGF beta 1 at less than half normal, around 10,000 or below. Values in the second quartile (4,000-5,000) indicate acceptable levels. If TGF beta 1 remains elevated after completing other work, it may signal missed factors or ongoing repair processes.
CDR3 represents resolution and salugenesis with inflammation mitigated, repair complete, debris cleared, and rhythm restored. The focus shifts to all-clear safety signals for the body rather than the home environment. Treatment emphasizes neuroendocrine support, parasympathetic activation, and tissue restoration. The body requires safety and sanctuary to heal beyond simple removal of triggers and detoxification.
Four phenotypes guide CDR3 readiness assessment. Phenotype A represents patients through CDR2. Panel testing includes inflammatory markers, CDR2 markers (GDF-15, FGF-21, T-helper cell panel), and viral assessment to distinguish between phenotype B (mitochondrial stress without immune suppression) and phenotype C (mitochondrial stress with immune suppression). Phenotype D indicates CDR3 readiness with all parameters normal.
Once in CDR3, KPV helps raise MSH levels, showing better efficacy when administered under these conditions rather than earlier phases. Deep stress resiliency work includes autonomic nerve stimulation, HRV training, and emotional tone work. Group-based treatment models leverage nervous system healing through community resonance, with patients treated in groups of six to nine meeting together through the healing journey.
Low MSH originates in the anterior hypothalamus, requiring effective portal circulation. Brain-healing interventions include BPC, RG3, cerebral (when available), Selank, CAX, DHEXA, and Lion's Mane. NeuroQuant studies assess brain healing status. MSH levels often fail to rise despite clinical improvement and GENIE resolution, possibly due to skipped mitochondrial work, unresolved CDR1 issues, or unaddressed emotional trauma affecting the brain.
GLP-1 agonists may be introduced in microdoses for hyperreactive MCAS patients early in treatment. These agents function well in CDR2 for metabolic support, weight management, neuroinflammation reduction, and insulin sensitivity improvement. The positioning of GLP-1s matters significantly for their effectiveness in CIRS contexts.
GLP-1 agonists are positioned carefully within the CDR recovery model. They are not appropriate when patients remain in active exposure, still inflamed, or failing visual contrast testing, as weight loss efforts will likely fail under these conditions. Once patients move out of the fire and into CDR2, GLP-1s become valuable tools due to their anti-inflammatory benefits, restorative qualities, brain healing properties, and metabolic stimulation. At higher doses, GLP-1s promote GAD 34 expression. By CDR3, GDF and FGF typically resolve GAD 34 needs, though GLP-1 use may have already addressed this pathway. Patients frequently report that GLP-1s create a turning point beyond weight loss, with improved brain clarity, increased energy, and enhanced quality of life.
Genine represents an underutilized option in the GAD 34 agonist category. Low heart rate variability serves as a clinical clue indicating impaired autonomic flexibility and reduced capacity to access safety states.
Direct vagal nerve stimulators like Truvaga and Sona clip to the ear and connect to the neck to send signals that improve parasympathetic tone. While these devices provide direct vagal contact, they should work alongside mind-body practices that build emotional resiliency rather than replacing them. Heart rate variability training teaches patients to improve coherence and develop mind-body skills. When buried trauma exists, which commonly occurs in this patient population, deeper interventions become necessary including EMDR, BTAP, and professional counseling to address emotional barriers preventing full healing. The emotional landscape functions as a vital sign requiring serious attention.
CDR3 involves restoring oxidative phosphorylation and shifting away from aerobic glycolysis reliance back toward mitochondrial oxidative phosphorylation for more efficient ATP production. Autoimmunity can present during CDR3, though exposures can trigger autoimmunity through mechanisms beyond a single-hit hypothesis. Loss of barriers and boundaries including leaky gut, leaky vessels, and compromised blood-brain barrier predisposes to autoimmunity by allowing noxious compounds into body compartments where they do not belong. ANA testing should be included as part of the readiness to heal gate alongside MMP9 and other inflammatory markers.
Functional medicine practitioners address autoimmunity through the standard protocol of cleaning up infections, supporting detoxification, changing diet, fixing the microbiome, and managing stress. Several compounds help bridge innate and adaptive immune responses while restoring normal adaptive immune tone. Majikare, a plant sterolin extract in a defined 100:1 ratio of sterols to sterolins, improves T-regulatory cell function and has extensive human clinical studies supporting its use. Originally developed for rheumatoid arthritis, it benefits various related conditions.
Low dose naltrexone temporarily reduces endorphins in the brain, and as they return two to three hours later, MHC class 2 cells activate, which raises T-regulatory cell function. LDN has been studied extensively in autoimmune conditions and is being incorporated into mental health applications as well. A course on LDN is being launched at George Washington University through the same here organization.
Oxytocin supports reduced autoimmunity through the mechanism of feeling safe in the world. Low dose immunotherapy whether administered sublingually or through injections provides exposure therapy benefits. TB500 and TA1 represent peptides that bridge innate and adaptive immune systems, though TA1 availability has been restricted to gray market sources. SPMs turn off autoimmune drive by stimulating macrophages and directing the immune system toward healing processes.
Rebuilding interventions including graded exercise, fasting, hot and cold therapy, intermittent hypoxia, NRF2 support, mitochondrial support, vagal tone work, sleep optimization, and lymphatic system support primarily occur in CDR3 rather than earlier stages. These therapies function optimally when patients are relatively healthy and function like training an untrained athlete to maximize engine capacity. When applied too early in CDR1 or CDR2, these interventions can worsen mitochondrial reserve, overwhelm patients with post-exertional malaise, or fail because the body lacks reserve to enter repair cycles.
Zone 2 heart rate training begins at 120-130 beats per minute for 10-15 minute sessions, building to 45 minutes several days per week. This approach invigorates the immune system, supports repair processes, immune tonification, and fat loss without emphasizing cardiovascular benefits. Intermittent fasting and caloric restriction are introduced once patients reach CDR3 as mitogens for improving resiliency and reserve.
VIP addresses the genomic piece of resolution and repair. PEA represents a stronger version of VIP that binds to additional receptors beyond VIP receptors and demonstrates more potent neurogenesis and anti-inflammatory characteristics, though it remains on a non-compound list with no therapeutic access. BPC 157, CAX, SANK, and DHEXA have been liberated from previous restrictions and are now available. These peptides particularly support immune regulation and brain healing aspects of CDR3. Cerebral is not currently accessible.
The Beyond Mold website contains extensive educational material including in-depth monographs and scientific treatments. A clinical primer and additional resources will be released over coming months. A book summarizing the complete model is scheduled for release in approximately one year, with several chapters co-authored with Neil Nathan. Multiple access options exist including a messaging program at $99 monthly providing unlimited reasonable access to the clinical team, individual appointments at accessible pricing, and group programs consisting of seven two-hour sessions totaling 14 hours of contact time. A 50-state telemedicine platform enables medication access, lab testing, and resources including binders, methylene blue, LDN, and VIP without requiring office visits. Lab panels can be ordered directly through the website.
Living in New Zealand provides access to clean air, water, and nutrient-dense food with rapid spoilage indicating freshness. Physical activity includes regular treadmill walking maintaining specific heart rate zones for at least 45 minutes, interval training, high-intensity training, wildlife photography, and kayaking. Sleep remains challenging with difficulty turning off brain activity, requiring high-dose melatonin and other interventions. Moving, breathing, eating well, and maintaining healthy mindset support overall function despite sleep difficulties.
Keep BetterHealthGuy in your library
Save the videos and channels worth coming back to, and find them again in one place.
